Evommune-linked entity granted 358K common shares

Evommune, Inc. reported an insider-related equity award involving an affiliated investment entity.

Rhea-AI Filing Summary

Evommune, Inc. reported an insider-related equity award involving an affiliated investment entity. On February 17, 2026, LSP 7 Cooperatief U.A., an entity associated with director and 10% owner Felice Isabel Verduyn-van Weegen, acquired 358,680 shares of common stock at $27.88 per share through a grant or award. Following this transaction, the entity held 5,288,313 common shares indirectly attributed to the reporting person, who disclaims beneficial ownership except to the extent of any pecuniary interest.

Insider Trade Summary

Grant/Award: 358,680 shares

Grant/Award 1 txn

Insider Verduyn-van Weegen Felice Isabel

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	358,680	$27.88	$10.00M

Holdings After Transaction: Common Stock — 5,288,313 shares (Indirect, By LSP 7 Cooperatief U.A.)

Footnotes (1)

1. F1. These securities are held by LSP 7 Cooperatief U.A. ("LSP 7"). LSP 7 Management BV ("LSP 7 Management") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Evommune (EVMN) disclose in this Form 4?

Evommune disclosed an equity award where LSP 7 Cooperatief U.A., an entity linked to director and 10% owner Felice Isabel Verduyn-van Weegen, acquired 358,680 common shares at $27.88 per share, increasing its indirectly attributed holdings to 5,288,313 shares.

Who is the reporting person in Evommune (EVMN)’s latest Form 4 filing?

The reporting person is Felice Isabel Verduyn-van Weegen, identified as a director and 10% owner of Evommune. The reported shares are held indirectly through LSP 7 Cooperatief U.A., an affiliated investment entity, rather than in her direct personal account.

How many Evommune (EVMN) shares were acquired in the reported transaction?

The filing shows an acquisition of 358,680 shares of Evommune common stock. These shares were obtained by LSP 7 Cooperatief U.A. via a grant or award, not an open-market purchase, at a reported price of $27.88 per share.

What is the total Evommune (EVMN) stake after this Form 4 transaction?

After the transaction, LSP 7 Cooperatief U.A., linked to the reporting person, held 5,288,313 shares of Evommune common stock. This figure reflects the indirect holdings attributed in the filing following the 358,680-share grant or award acquisition.

Does the Evommune (EVMN) insider fully own the reported shares personally?

The reporting person disclaims full beneficial ownership. The shares are held by LSP 7 Cooperatief U.A., and she notes she only benefits to the extent of any pecuniary interest, meaning the economic benefit she may personally derive from the holdings.

Was the Evommune (EVMN) insider transaction a market buy or a grant?

The transaction is classified as a grant, award, or other acquisition, not a market purchase. The Form 4 uses code “A” and describes the action as a grant or award acquisition, indicating the shares were awarded rather than bought on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 09:19 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Verduyn-van Weegen Felice Isabel

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1841 PAGE MILL ROAD, SUITE 100

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		A		358,680	A	$27.88	5,288,313	I	By LSP 7 Cooperatief U.A.(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These securities are held by LSP 7 Cooperatief U.A. ("LSP 7"). LSP 7 Management BV ("LSP 7 Management") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein.

	/s/ Gregory S. Moss, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.